Navidea Biopharmaceuticals, Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (22)

Latest Posts

About This Stock More About This Stock
Week In Review: Xynomic Signs $502 Million Deal For Boehringer's RAF Inhibitor
Article By: ChinaBio® Today
Saturday, November 4, 2017 4:58 PM EDT
Xynomic Pharma, a US-Shanghai clinical-stage oncology drug developer, acquired exclusive global rights to a 2nd-generation RAF inhibitor from Boehringer Ingelheim. Xynomic, hoping BI 882370 is a best-in-class drug, agreed to a $502 million package.
In this article: BLRX, ILMN, TEVA, NAVB Also: INTC, BABA
Read
Sapiens International & Navidea Biopharmaceutical - Sell Signals
Article By: Jim Van Meerten
Saturday, November 7, 2015 2:25 PM EDT
Today I deleted Sapiens International (Nasdaq:SPNS) and Navidea Biopharmacuetical (NYSE:NAVB) for the Barchart Van Meerten Speculative portfolio for negative price momentum.
In this article: SPNS, NAVB
Read
Buy Signals - ABCD, CACB, NAVB
Article By: Jim Van Meerten
Wednesday, July 15, 2015 2:14 PM EDT
Today I added Cambium Learning Group, Cascade Bancorp and Navidea Biopharmaceuticals to my portfolio for superior price performance.
In this article: ABCD, CACB, NAVB
Read
EC Our 3 Potential Triple Digit Biotech Winners Revisited
Article By: Bret Jensen
Tuesday, February 10, 2015 2:29 PM EDT
We’ve enjoyed a lot of success with biotechs lately, most notably Avanir that got bought out and gave Small Cap Gems subscribers a profit of 214.7% in only five months.
In this article: NAVB, INCY, AGEN, CRIS, AVNR
Read
2 Triple Digit Winners For Under $2
Article By: Bret Jensen
Wednesday, January 21, 2015 8:12 AM EDT
Small companies in the biotech, medical device, and biopharma spaces are inherently volatile and tend to have many bumps in the road as they try to establish their businesses in a very competitive market.
In this article: NAVB, ETRM, ZLTQ, LCI, AGEN, HALO
Read

PARTNER HEADLINES

Latest Tweets for $NAVB

No tweets yet!